Sharon A. Kidd

Sharon A. Kidd

Auto-generated profile, based on publicly available information

Sharon A. Kidd

Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplantation, https://ror.org/043mz5j54University of California, San Francisco, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2023 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Open access
PDF file
ALAve M. Lachiewicz
Ave M. Lachiewicz
TSTracy M. Stackhouse
Tracy M. Stackhouse
KBKristin Burgess
Kristin Burgess
DBDebra Burgess
Debra Burgess
HAHoward F. Andrews
Howard F. Andrews
SKSharon A. Kidd
Sharon A. Kidd
This study was designed to increase our understanding about characteristics and the impact of sensory symptoms (SS) and signs of hyperarousal (HA) in individuals with fragile X syndrome (FXS) from childhood through early adulthood and by gender. Data derived from the Fragile X Online Registry With Accessible Research Database (FORWARD), a natural history study of FXS, were analyzed using descriptive statistics and multivariate linear and logistic regression models to examine SS and signs of HA, their impact on behavioral regulation and limitations on the subject/family. The sample (N = 933) consisted of 720 males and 213 females. More males were affected with SS (87% vs. 68%) and signs of HA (92% vs. 79%). Subjects who were endorsed as having a strong sensory response had more comorbidities, including behavioral problems. The predominant SS was difficulty with eye gaze that increased with age in both genders. As individuals age, there was less use of non-medication therapies, such as occupational therapy (OT)/physical therapy (PT), but there was more use of psychopharmacological medications and investigational drugs for behaviors. Multiple regression models suggested that endorsing SS and signs of HA was associated with statistically significantly increased ABC-C-I subscale scores and limited participation in everyday activities. This study improves our understanding of SS and signs of HA as well as their impact in FXS. It supports the need for more research regarding these clinical symptoms, especially to understand how they contribute to well-known behavioral concerns.

28 January 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KAKatrina Abuabara
Katrina Abuabara
SKSharon A. Kidd
Sharon A. Kidd
MYMorgan Ye
Morgan Ye
JTJanell Tully
Janell Tully
NTNatalie Tomaszewski
Natalie Tomaszewski
SLSinéad M. Langan
Sinéad M. Langan

7 July 2026 in Journal of Human Immunity
Verified
Journal Article
Open access
LWLena Winestone
Lena Winestone
BLBrent R. Logan
Brent R. Logan
XLXuerong Liu
Xuerong Liu
OWOlatundun Williams
Olatundun Williams
EDElizabeth A. Dunn
Elizabeth A. Dunn
EHElie Haddad
Elie Haddad
Winestone et al. demonstrate that in 796 children with SCID transplanted with nonsibling donors between 1982 and 2020, survival was 18.8% lower among Black patients, 14.4% lower among Asian/Pacific Islander patients, and 6.9% lower among Hispanic patients compared with non-Hispanic White patients (P < 0.01). Newborn screening for SCID mitigates wide disparities between Black and non-Hispanic White patients.

17 December 2025 in Journal of Human Immunity
Verified
Journal Article
Open access
VBVirdette L. Brumm
Virdette L. Brumm
SKSharon A. Kidd
Sharon A. Kidd
BLBrent R. Logan
Brent R. Logan
FCFarheen Chunara
Farheen Chunara
JHJennifer Heimall
Jennifer Heimall
ASAmi J Shah
Ami J Shah
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe combined immunodeficiency (SCID). Since the initiation of newborn screening (NBS), survival rates have improved significantly, but the impact of HCT upon neurodevelopment for patients with SCID requires more investigation. We performed a cross-sectional study of subjects with SCID in North America to assess the impact of NBS, transplant conditioning regimen, and genotype on neurodevelopmental outcomes after HCT. 69 subjects with SCID from 17 PIDTC centers (excluding those with ADA deficiency), ages 6–16 years, received comprehensive standardized neurodevelopmental testing of cognitive, behavioral, and emotional function. Compared with the normative population, our subjects performed in the average range. We found no impact of NBS, chemotherapy conditioning, or genotype. Multivariate analysis revealed a significant decrease in IQ in subjects whose families earned <$50,000 per year. We recommend that children treated by HCT for SCID be monitored with periodic cognitive and behavioral assessments for deficits that could potentially impact long-term ND outcomes.